Myasthenia Gravis Pipeline Insight

DelveInsight’s, “Myasthenia Gravis Pipeline Insight, 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Myasthenia Gravis  pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Myasthenia Gravis Understanding

Myasthenia Gravis Overview

Myasthenia gravis (MG) is the most common disorder affecting the neuromuscular junction (NMJ) of the skeletal muscles. It usually involves muscles of the eyes, throat, and extremities. The reduced transmission of electrical impulses across the neuromuscular junction due to the formation of autoantibodies against the specific postsynaptic membrane proteins consequently causes muscle weakness. Myasthenia gravis causes a significant number of complications. These include myasthenic crisis, an acute respiratory paralysis that requires intensive care, as well as adverse events due to long term medication treatment like opportunistic infections and lymphoproliferative malignancies.
Myasthenia gravis has a prevalence of 20 per 100,000 population in the US. It exhibits a female predominance in those less than 40 years of age and a male predominance in those greater than 50 years of age. Childhood MG is quite uncommon in the western populations but is prevalent in Asian countries, with the involvement of around 50% of patients aged less than 15 years.
The mainstay of myasthenia gravis (MG) treatment involves cholinesterase enzyme inhibitors and immunosuppressive agents. Symptomatic treatment with acetylcholinesterase inhibitors like pyridostigmine increases ACh levels at the neuromuscular junction. Immunotherapy includes glucocorticoids, azathioprine, and second-line agents like cyclosporine. Monoclonal antibodies such as rituximab and eculizumab are used for drug-resistant cases. Intravenous immunoglobulins (IVIG) and plasmapheresis are crucial for myasthenic crisis. Thymectomy is indicated for specific subtypes of MG, excluding MuSK MG and non-thymomatous ocular MG without generalization.
The complication of myasthenia gravis includes myasthenic crisis, usually secondary to infections, stress, or acute illnesses.
Treatment complications include long term steroid effects like osteoporosis, hyperglycemia, cataracts, weight gain, hypertension, and avascular necrosis of the hip. There is also the risk of lymphoproliferative malignancies, as well as opportunistic infections such as systemic fungal infections, tuberculosis, and Pneumocystis carinii pneumonia with chronic immunosuppressive therapy. Symptoms include cramps, lacrimation, increased salivation, muscular weakness, muscular fasciculation, paralysis, diarrhea, and blurry vision.

“Myasthenia Gravis Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Myasthenia Gravis pipeline landscape is provided which includes the disease overview and Myasthenia Gravis treatment guidelines. The assessment part of the report embraces, in depth Myasthenia Gravis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myasthenia Gravis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest Myasthenia Gravis Pipeline , emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Myasthenia Gravis Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Myasthenia Gravis R&D. The therapies under development are focused on novel approaches to treat/improve Myasthenia Gravis. 

Myasthenia Gravis Emerging Drugs Analysis

This segment of the Myasthenia Gravis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Myasthenia Gravis Emerging Drugs

IMVT-1402: Immunovant/ Roivant Sciences

IMVT-1402 is a next-generation, SC administered anti-FcRn mAb developed by Immunovant for the treatment of IgG-mediated autoimmune diseases. It effectively lowers pathogenic IgG while preserving normal albumin and cholesterol levels, mitigating safety issues seen with previous FcRn inhibitors. IMVT-1402 is positioned as Immunovant’s lead asset and is advancing through clinical trials for conditions such as myasthenia gravis and other autoimmune disorders. Immunovant has strategically opted not to pursue regulatory approval for batoclimab in the indications of myasthenia gravis. Instead, the company aims to capitalize on insights gained from batoclimab clinical studies to guide and expedite the development of its next-generation program, IMVT-1402. Currently, the drug is in Phase III stage of its clinical development for the treatment of Myasthenia Gravis.

KYV-101: Kyverna Therapeutics

KYV-101 is an autologous, fully human anti-CD19 CAR T-cell therapy developed by Kyverna Therapeutics to treat B cell-driven autoimmune diseases such as generalized myasthenia gravis (gMG). It works by engineering a patient’s own T cells to target and eliminate CD19-positive B cells, thereby reducing autoantibody production and potentially “resetting” the immune system. The therapy aims to provide long-lasting remission with a single infusion rather than chronic immunosuppression. Currently, the therapy is being evaluated under Phase II/III stage of its development for the treatment of Myasthenia gravis..

CABA-201: Cabaletta Bio

Resecabtagene autoleucel (CABA-201) is an autologous, fully human anti-CD19 CAR T-cell therapy developed by Cabaletta Bio for treating B cell-mediated autoimmune diseases such as generalized myasthenia gravis (gMG). It works by reprogramming a patient’s own T cells to target and eliminate CD19-positive B cells, aiming to remove autoreactive B cells that produce pathogenic antibodies. This deep B-cell depletion may reset the immune system and induce long-term remission. Currently, the drug is in Phase I/II stage of development for the treatment of Myasthenia Gravis.

Further product details are provided in the report……..

Myasthenia Gravis Therapeutic Assessment

This segment of the report provides insights about the different Myasthenia Gravis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Myasthenia Gravis 

There are approx. 25+ key companies which are developing the therapies for Myasthenia Gravis. The companies which have their Myasthenia Gravis drug candidates in the most advanced stage, i.e. Phase III include,  Immunovant, Roivant Sciences and others.

Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Myasthenia Gravis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal 
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Myasthenia Gravis Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Myasthenia Gravis Clinical Trial Activities

The Myasthenia Gravis Pipeline report provides insights into different Myasthenia Gravis Clinical Trial candidates within phase II, I, preclinical and discovery stage. It also analyses Myasthenia Gravis therapeutic drugs key players involved in developing key drugs. 

Myasthenia Gravis Pipeline Development Activities

The Myasthenia Gravis Clinical Trial Analysis Report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myasthenia Gravis drugs.

Myasthenia Gravis Report Insights

• Myasthenia Gravis Pipeline Analysis
• Myasthenia Gravis Therapeutic Assessment
• Myasthenia Gravis Unmet Needs
• Impact of Myasthenia Gravis Drugs

Myasthenia Gravis Report Assessment

• Myasthenia Gravis Pipeline Product Profiles
• Myasthenia Gravis Therapeutic Assessment
• Myasthenia Gravis Pipeline Assessment
• Inactive drugs assessment
• Myasthenia Gravis Market Unmet Needs

Discover actionable insights into the Myasthenia Gravis market trends , epidemiology trends, and forecast through 2034 to stay ahead in emerging therapies.

Key Questions Answered In The Myasthenia Gravis Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Myasthenia Gravis drugs?
• How many Myasthenia Gravis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myasthenia Gravis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Myasthenia Gravis therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Myasthenia Gravis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• RemeGen
• Takeda
• Immunovant Sciences
• Alexion Pharmaceuticals
• Regeneron Pharmaceuticals
• Cabaletta Bio
• Momenta Pharmaceuticals
• Kyverna Therapeutics
• Amgen
• COUR Pharmaceutical Development Company

Key Products

• Telitacicept
• TAK-079
• RVT-1401
• Ravulizumab
• Pozelimab
• MuSK-CAART
• M281
• KYV-101
• Inebilizumab
• CNP-106

Explore comprehensive insights into Myasthenia Gravis epidemiology trends , patient population forecasts, and growth opportunities through 2034 for strategic decision-making.